~~<i id='1F9EE991B7'><strike id='1F9EE991B7'><tt id='1F9EE991B7'><pre id='1F9EE991B7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：focus 2025-10-01 17:19:44 - browse：1337

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Morgan Health, with ambitious aims, wants you to know it’s still here

leisure time

focus

entertainment

Wikipedia

focus

Wikipedia

AdobeAlawsuitbetweenalargehospitalsystemandadominantvendorthatworksforhealthinsurancecompaniesisgett

WSS

Medicare Advantage enrollment grows 7.1% to 33.4 million people

The biotech scorecard for Q1: 17 stock

Videos point to link between seizures and unexplained toddler deaths

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Goldman Sachs launches $650M fund for life science investments

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

focus

leisure time

In Memoriam: Notable people who died in 2023

Obamacare plans could cover weight loss drugs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

White House finalizes ITC's import ban of latest Apple Watches

Jerome Adams on the need for new antivirals for Covid

Opioid cravings were reduced by anti

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Reporting on presidential health from Reagan to Trump and Biden

Hepatitis C has a cure — but many Americans still lack access to it

Congress may force more Covid

focus

3 medical device trends to watch in 2024

Federal weight loss drug coverage is 30 years out of date

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Hospitals are piloting generative AI tools as regulators play catch

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

WATCH: Why do our ears pop?

entertainment

Wikipedia

focus

Wikipedia